Paris office represents the European Investment Bank (EIB) on its €20 million financing of MedinCell, an innovative French biotech company specializing in injectable medical treatments with controlled and extended action.
Willkie recently advised EIB on its €20 million financing of MedinCell. The financing will enable MedinCell to develop innovative injectable controlled-acting and prolonged treatments in order to replace daily medication with subcutaneous or localized injections and improve the quality of life of patients.
The financing structure put in place in this transaction was adapted to the specific needs of MedinCell thanks to the European guarantee under the Juncker plan, one of the main objectives of which is to support the development of innovative companies in Europe.
The Willkie deal team was led by partner Amir Jahanguiri and included associate Cédric Gamambaye Dionmou.